63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details


Clinical trials : 363 Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05232149
(ClinicalTrials.gov)
February 202220/12/2021A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune ThrombocytopeniaA Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune ThrombocytopeniaPrimary Immune ThrombocytopeniaDrug: Orelabrutinib( lower dose);Drug: Orelabrutinib( higher dose)Beijing InnoCare Pharma Tech Co., Ltd.NULLNot yet recruiting18 Years80 YearsAll30Phase 2China